Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

49 results about "Eclampsia preeclampsia" patented technology

Preeclampsia (pree-i-KLAMP-see-uh) and eclampsia (ih-KLAMP-see-uh) are pregnancy-related high blood pressure disorders. In preeclampsia, the mother’s high blood pressure reduces the blood supply to the fetus, which may get less oxygen and fewer nutrients.

Method for constructing pre-eclampsia risk assessment prediction model, and application thereof

PCT designated stage expiredWO2025111763A1Medical simulationProtein markersDisease
Provided in the present invention are a method for constructing a pre-eclampsia risk assessment prediction model, and a prediction product, a prediction system, and a related application of the method. Specifically, the method of the present invention comprises: constructing a logistic regression analysis model on the basis of acquired clinical indexes of a pregnant woman, and obtaining the prior probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman; performing median-of-multiples calibration on an acquired MAP, IGFBP1 and / or PLGF of the pregnant woman, and respectively constructing a multivariate normal distribution model for a sick pregnant woman and a multivariate normal distribution model for a healthy pregnant woman on the basis of an MAP MoM value and an IGFBP1 MoM value and / or a PLGF MoM value, so as to obtain the conditional probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman; and in view of the prior probability and the conditional probability, calculating the posterior probability of early-onset pre-eclampsia or late-onset pre-eclampsia in the pregnant woman on the basis of a Bayesian model. In the present invention, the detection of related protein markers and the obtaining of maternal clinical information data are relatively easy, the accuracy of predicting early-onset pre-eclampsia and late-onset pre-eclampsia is relatively high, and clinical popularization and application are facilitated; therefore, the present invention is of great value to the prevention and early diagnosis of a disease.
Owner:BGI GENOMICS CO LTD +1

Pre-eclampsia mouse model as well as construction method and application thereof

The invention discloses a preeclampsia mouse model. The preeclampsia mouse model is constructed by the following method: (1) combining a female mouse with a male mouse; (2) in the middle stage of pregnancy, intragastric administration of hypoxanthine and oteracil potassium salt is carried out on the pregnant mouse for a period of time; the invention also discloses a construction method and application of the gene. The invention provides a novel preeclampsia modeling mode, hypoxanthine and oteracil potassium salt are combined for use, and the administration dosage and the administration mode of hypoxanthine and oteracil potassium salt are controlled, so that the serum uric acid level of a model mouse is stably increased, preeclampsia change occurs in the model mouse, and the model mouse can be used for treating preeclampsia. The stability, specificity and pathophysiology characteristics of the model are ensured to be similar to those of human preeclampsia, so that the uric acid-induced preeclampsia mouse model is successfully constructed. The uric acid induced preeclampsia mouse model provides a valuable tool for researching the pathogenesis of preeclampsia, evaluating a new treatment method and understanding the effect of serum hyperuricemia in preeclampsia.
Owner:THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV

Pre-eclampsia animal model construction method based on RASA3 target and application

The invention discloses a construction method and application of a preeclampsia animal model based on an RASA3 target, and belongs to the technical field of biomedicine.The preeclampsia animal model is constructed by injecting Ad-RASA3 into a pregnant mouse and monitoring pathological indexes, related to preeclampsia, of the pregnant mouse. According to the method, the animal model with preeclampsia-like clinical symptoms can be stably induced, the abnormal change of the uterine spiral artery remodeling process can be systematically monitored, the method is high in operation controllability and model stability, and an effective tool can be provided for deeply researching the pathogenesis of preeclampsia and developing a novel diagnosis and treatment strategy.
Owner:THE WEST CHINA SECOND UNIV HOSPITAL OF SICHUAN

Application of fructus amomi water extract and / or vanillic acid in preparation of medicine for preventing and / or treating preeclampsia

The invention discloses application of a fructus amomi water extract and / or vanillic acid in preparation of a medicine for preventing and / or treating preeclampsia. The invention also discloses application of the fructus amomi water extract and / or vanillic acid in preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia, or a medicine for reversing weight reduction of placenta caused by preeclampsia, or a medicine for recovering intrauterine growth limitation of fetuses caused by preeclampsia, or a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia. Or a medicine for recovering placenta tissue pathological injury or placenta dysfunction caused by preeclampsia, or a medicine for reversing placenta efficiency reduction caused by preeclampsia, or a medicine for repairing colon barrier injury or intestinal permeability increase caused by preeclampsia; or the bifidobacterium bifidum in the intestinal tract of a preeclampsia patient is enriched. The traditional Chinese medicine composition overcomes the limitations of single effect and adverse reaction of gastrointestinal tracts in the current preeclampsia treatment medicine.
Owner:SOUTHERN MEDICAL UNIVERSITY

Pre-eclampsia biomarker and application thereof

The invention provides a biomarker for predicting the preeclampsia risk, application of the biomarker and a method for detecting whether an object has the preeclampsia risk or not. According to the method for detecting whether the object has the preeclampsia risk, preeclampsia risk prediction is carried out on all pregnant women in the early and middle stages of pregnancy, whether preeclampsia high-risk groups exist or not is not distinguished, and risk prediction can be carried out before symptoms occur; different types of free RNA in blood are associated with preeclampsia, the biomarker is used for constructing a preeclampsia prediction model in at least 300 samples, and the specificity of the preeclampsia prediction model during pregnancy can be improved to 85% or above.
Owner:BGI GENOMICS CO LTD +1

Pre-eclampsia risk assessment and prediction model based on metabonomics and application thereof

The invention provides a metabonomics-based preeclampsia risk assessment prediction model construction method, a prediction model, application of metabolites, a metabolite detection kit, a prediction product, a prediction system and related application thereof. Specifically, clinical indexes and metabolite data of a pregnant woman serve as input, whether the pregnant woman suffers from preeclampsia or not serves as output, model construction is conducted through a machine learning method, and a preeclampsia risk assessment and prediction model is obtained. The metabolite is selected from at least one of 4-hydroxyphenyllactic acid, homovanillic acid, ornithine, sarcosine, adenosine monophosphate and 3-methylbutyryl carnitine. According to the invention, not only are six metabolite markers strongly associated with preeclampsia found, but also effective prediction of early preeclampsia and late preeclampsia is realized by establishing a prediction model, and the method has extremely high clinical value.
Owner:BGI GENOMICS CO LTD

Application of fructus amomi volatile oil and / or bornyl acetate in preparation of medicine for preventing and / or treating preeclampsia

PendingCN118924856Agood treatment effectrepair structureAntipyreticDigestive systemPLACENTAL FUNCTIONSPharmaceutical Substances
The invention discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating preeclampsia. The invention also discloses application of fructus amomi volatile oil and / or bornyl acetate in preparation of a medicine for preventing and / or treating hypertension caused by preeclampsia, or a medicine for preventing and / or treating proteinuria caused by preeclampsia, or a medicine for reversing placenta weight reduction caused by preeclampsia. The invention relates to a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia, a medicine for recovering angiogenesis and anti-angiogenesis factor imbalance caused by preeclampsia, or a medicine for relieving colitis caused by preeclampsia, or a medicine for recovering fetal intrauterine growth limitation caused by preeclampsia, or a medicine for recovering placenta tissue pathological damage or placenta dysfunction caused by preeclampsia. The invention also relates to application of the traditional Chinese medicine composition in medicines for repairing colon barrier injury or intestinal permeability increase caused by preeclampsia. The traditional Chinese medicine composition overcomes the limitations of single effect and adverse reaction of gastrointestinal tracts in the current preeclampsia treatment medicine.
Owner:SOUTHERN MEDICAL UNIVERSITY

Application of baicalin in preparation of medicine for treating preeclampsia by inhibiting NETs-induced trophoblast ferroptosis

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a medicine for treating preeclampsia by inhibiting trophoblast ferroptosis induced by NETs. The baicalin inhibits downstream signal transduction by specifically interfering a key activation step of PKC [beta] 2 and a membrane translocation process coupled with a second signal, and finally plays a role in inhibiting ferroptosis of trophoblasts. The discovery provides a brand new perspective for understanding the molecular action mechanism of the medicine. According to the application, baicalin influences ferroptosis induced by NETs in trophoblast cells by inhibiting membrane translocation and activation of PKC beta2, so that the biological function of baicalin is exerted. The discovery of the mechanism further deepens the important significance of people on NETs and baicalin in disease induction and treatment, and a thought is provided for research and development of a new treatment scheme for preeclampsia.
Owner:MATERNAL & CHILD HEALTH CARE HOSPITAL OF SHANDONG PROVINCE SHANDONG UNIV

Application of TMEM106A as target spot in preparation of diagnostic kit and targeted therapeutic drug

The invention discloses an application of TMEM106A as a target spot in preparation of a diagnostic kit and a targeted therapeutic drug. Relates to the technical field of immunodiagnosis. Specific applications are provided. The invention discloses a key effect of TMEM106A in podocyte injury related to preeclampsia. TMEM106A is significantly down-regulated in urine of a PE patient, is closely related to podocyte injury and inflammatory response, and can be used as an early noninvasive diagnostic marker; meanwhile, the targeted podocyte up-regulation TMEM106A has remarkable anti-inflammatory and kidney protection effects, and a theoretical basis and practical feasibility are provided for targeted therapy of PE-related podocyte injury. The invention provides a new way for early precise diagnosis and intervention strategy of PE, and has wide clinical application prospect.
Owner:THE SECOND HOSPITAL OF SHANDONG UNIV

A method for predicting gestational hypertension in early pregnancy and its application

PendingCN122314366AThe risk of gestational hypertension (including preeclampsia) is valid and robustReduced risk of pregnancy-induced hypertension (including preeclampsia)Transcription initiation siteObstetrics
This invention relates to a group of genes associated with gestational hypertension, a method for predicting gestational hypertension in early pregnancy using these genes, and related applications. Specifically, this invention obtains transcript start site feature values ​​from at least one of the following genes from the cfDNA sample of a pregnant woman: LOC124902572, EEF1A1P16, LOC105369767, GOLM2, CDRT7, MEIS3, and LOC105376108. These transcript start site feature values ​​are then input into a prediction model, and the output results are used to determine the risk of gestational hypertension. The number of sequences in the transcript start site region after correction based on the transcript start site feature values ​​is also considered. The prediction model obtained by this invention can effectively and robustly predict the risk of gestational hypertension (including preeclampsia) in early pregnancy, assisting doctors in early pregnancy intervention and reducing the risk of gestational hypertension.
Owner:BGI GENOMICS CO LTD +1

Application of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for the treatment of preeclampsia

The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for treating preeclampsia, belonging to the field of biological medicine technology. The present invention provides the use of nano-microvesicles derived from mesenchymal stem cells in the preparation of drugs for treating preeclampsia. Experiments have shown that after extracting secreted microvesicles from umbilical cord mesenchymal stem cells, they are used to treat preeclampsia rat animal models. The hucMSC-derived microvesicles have the effect of reducing blood pressure and 24h proteinuria in preeclampsia model rats, improving preeclampsia-like symptoms in rats, and can increase the weight of offspring and improve fetal development, providing a new direction for the treatment of preeclampsia.
Owner:AFFILIATED HOSPITAL OF JINING MEDICAL UNIV

Use of fabp4 in the preparation of products for diagnosing preeclampsia and drugs for treating preeclampsia

The application provides application of FABP4 in preparation of a preeclampsia diagnosis product and a preeclampsia treatment drug, belongs to the technical field of biotechnology, and in particular, the application provides application of a FABP4 detection reagent in preparation of a preeclampsia diagnosis product and application of a FABP4 inhibitor in preparation of a preeclampsia treatment drug, and the application proves for the first time that FABP4 can be used as a preeclampsia diagnosis marker and proves that FABP4 can be directly used as a treatment target of preeclampsia, provides a diagnosis and treatment target for diagnosis and treatment of preeclampsia, lays a solid foundation for development of a preeclampsia treatment drug, and opens up a new way for precise treatment of preeclampsia.
Owner:DONGTAI PEOPLES HOSPITAL

A folic acid derivative, its preparation method, and its application in preventing ferroptosis.

This invention belongs to the field of pharmaceutical application technology, specifically relating to a folic acid derivative, its preparation method, and its application in preventing and treating ferroptosis. The folic acid derivative of this invention comprises compounds represented by general formula (I) and their pharmaceutically acceptable salts. The folic acid compounds provided by this invention, by introducing a lipophilic group or a specific group at the R position, yield compounds with good ferroptosis inhibitory activity, which can be used to treat non-alcoholic steatohepatitis, acute liver injury, cardiomyopathy, drug-induced cardiotoxicity, atherosclerosis, acute kidney injury, renal fibrosis, pneumonia, preeclampsia, osteoporosis, osteoarthritis, traumatic brain injury, and neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and epilepsy.
Owner:SHANDONG NORMAL UNIV

Pre-eclampsia environment chemical substance risk prediction method based on multi-dimensional data

The invention discloses a pre-eclampsia environmental chemical substance risk prediction method based on multi-dimensional data. The method comprises the following steps: firstly, analyzing environmental chemical substance concentration based on exposure science, and calculating exposure risk frequency score; thirdly, comprehensively evaluating the correlation degree of environmental chemicals and preeclampsia based on epidemiology, and calculating an epidemiology risk score; then performing a cytotoxicity experiment based on toxicology of an in-vitro experiment to detect the influence of environmental chemical substances on cell activity; then, on the basis of metabonomics, the interference degree of environmental chemical substances is quantified through pathway enrichment analysis, and a metabolic interference score is calculated; calculating toxicological scores based on the toxicity database; and finally, integrating the various groups of chemical scores, calculating the risk scores of the environmental chemical substances and generating a preeclampsia foreign substance priority list. By fusing multi-omics and multi-source data, the environmental chemical substances are comprehensively and accurately detected and evaluated, and accurate prevention and control of high-risk chemicals and risk early warning of corresponding crowds are facilitated.
Owner:ANHUI MEDICAL UNIV

Methods and systems for treating pregnancy-related hypertensive disorders comprising anti-sEng and anti-sFlt-1 antibodies

Disclosed are methods and apparatuses for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using ex vivo treatment with an anti-sFlt-1 antibody and an anti-sEng antibody bound to a solid support in order to reduce blood levels of sFlt-1 and sEng. The present disclosure relates to methods, systems, devices, and apparatuses for treating pregnancy-related hypertensive disorders such as pre-eclampsia and eclampsia.
Owner:AGGAMIN LLC

Application of anaerobic bacteria sensitive antibiotics in the preparation of drugs for treating preeclampsia

The present application discloses the use of anaerobic-sensitive antibiotics in the preparation of drugs for the treatment of preeclampsia. Fusobacterium nucleatum is closely related to the clinical phenotype of preeclampsia, and has the effect of directly inducing the occurrence of preeclampsia, and clarifies the key pathogenic bacteria of preeclampsia. Taking Fusobacterium nucleatum as a target for preeclampsia, using anaerobic-sensitive antibiotics to target and eliminate this strain can improve the phenotypes of preeclampsia including hypertension, proteinuria, fetal growth restriction, and placental dysplasia.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY

Diagnostic marker for preeclampsia

The invention discloses a diagnostic marker for preeclampsia, relates to the technical field of biological medicines, and comprises application of a reagent for detecting PDCD5 in preparation of a diagnostic tool for preeclampsia. Experiments prove that the PDCD5 gene and the expression product thereof are differentially expressed in normal placenta tissue and peripheral blood as well as preeclampsia placenta tissue and peripheral blood, so that the PDCD5 gene and the expression product thereof can be used as biomarkers for diagnosing preeclampsia.
Owner:HUBEI UNIV OF ARTS & SCI

Application of Agaricus bisporus peptide in preeclampsia

The present invention belongs to the field of biomedicine and relates to the application of Agaricus bisporus polypeptides in preeclampsia. The present invention relates to the use of Agaricus bisporus polypeptides in the preparation of products for promoting the invasion and migration of placental trophoblastic cells or preventing and treating preeclampsia in subjects. The present invention also relates to products containing Agaricus bisporus polypeptides that promote the invasion and migration of placental trophoblastic cells or prevent and treat preeclampsia in subjects. The present invention has found that Agaricus bisporus polypeptides have the effect of promoting the proliferation and migration of human chorionic trophoblastic cells, and the promotion of the proliferation and migration of human chorionic trophoblastic cells reflects the therapeutic effect of preeclampsia, so Agaricus bisporus polypeptides can be used to treat and prevent preeclampsia in subjects.
Owner:FUYANG NORMAL UNIVERSITY

Application of AhR gene in preeclampsia detection

The invention provides an application of an AhR gene in preeclampsia detection and an application of a product for detecting the polymorphism of the AhR gene in preparation of a preparation for detecting preeclampsia. The polymorphism of the AhR gene is related to occurrence of PE, rs2158041T and rs713150G are protection factors for occurrence of diseases, and the AhR gene is a susceptible gene of the diseases. The AhR gene polymorphism is found to be related to the preeclampsia for the first time, and the risk that a subject suffers from the preeclampsia can be judged by detecting the distribution of the AhR gene polymorphism of the subject, so that a clinician is guided to provide a prevention scheme or a treatment scheme for the subject.
Owner:KUNMING MEDICAL UNIVERSITY

Prediction model of preeclampsia risk and construction method and application thereof

The invention belongs to the technical field of biomedicine, and particularly relates to a pre-eclampsia risk prediction model and a construction method and application thereof. The prediction model takes the pre-pregnancy body mass index as an input factor and takes ethnic, assisted reproduction and whether a primary puerpera or not as adjustment variables to carry out restrictive cubic spline analysis to obtain a correlation curve of the pre-pregnancy body mass index and the preeclampsia risk; the curve of the correlation between the pre-pregnancy body mass index and the preeclampsia risk is an inverted L-shaped curve, and the inflection point of the curve of the correlation between the pre-pregnancy body mass index and the preeclampsia risk is used as a risk threshold value to evaluate the preeclampsia risk. The risk threshold is determined, and a basis is provided for judging the preeclampsia risk.
Owner:URUMQI MATERNAL & CHILD HEALTH HOSPITAL

Application of FTO, interference sequence of FTO and application of interference sequence

The invention relates to the technical field of medicine preparation, and particularly discloses application of FTO in preparation of a product for diagnosing preeclampsia, an interference sequence of the FTO and application of the interference sequence, and the FTO sequence is as shown in SEQ ID NO.1. The FTO can be used as an effective component of a preparation for diagnosing preeclampsia. Meanwhile, interference sequences FTO-RNAi (118151-1), FTO-RNAi (118152-2) and FTO-RNAi (118153-1) which can be used for preparing the medicine for treating preeclampsia are screened out through FTO, and tests prove that the interference sequences can obviously weaken attack of hypoxia-induced preeclampsia.
Owner:NINGXIA MEDICAL UNIV

Application of overexpression hsaCLNS1A2 reagent in preparation of medicine for treating preeclampsia

The invention belongs to the technical field of biology, and particularly relates to application of a reagent for overexpressing hsaCLNS1A2 in preparation of a medicine for treating preeclampsia, the placenta tissues of a normal puerpera and a PE puerpera are sequenced by RNA sequencing, hsaCLNS1A2 is determined to be specific circRNA, and the influence of hsaCLNS1A2 on placental trophoblast pyroptosis and invasion and migration is clarified.
Owner:NINGXIA MEDICAL UNIV

Pre-eclampsia piRNA non-invasive diagnostic marker, diagnostic kit and application

The invention discloses a preeclampsia piRNA noninvasive diagnostic marker, a diagnostic kit and application, and belongs to the technical field of molecular biology, the marker is piR-002094, and the nucleotide sequence of the marker is shown as SEQ ID NO: 1. The marker disclosed by the invention can be applied to preparation of kits and preparation of therapeutic drugs of the kits. The kit comprises a specific primer and a standardized reagent, and can be used for sensitively detecting the expression (AUC = 0.779) of piR-002094 in plasma. The piR-002094 inhibitor (SEQ ID NO: 7) provides a new strategy for preeclampsia treatment by inhibiting the piR-002094 to reduce the secretion of IL-6 (Interleukin-6).
Owner:GUANGZHOU FENGHUA BIOENG

Application of traditional Chinese medicine monomer in preparation of medicine for treating preeclampsia

The invention is applicable to the technical field of biological medicine, and provides application of a traditional Chinese medicine monomer in preparation of a medicine for treating preeclampsia, the traditional Chinese medicine monomer is rhynchophylline, and the rhynchophylline is clear in source, high in safety and pure in structure. Retrieval shows that no research report or patent disclosure for the rhynchophylline for preeclampsia treatment exists at present, and no systematic evaluation of the rhynchophylline under a multi-model system exists. According to the invention, a multi-model system is constructed for the first time, the intervention effect of the rhynchophylline on the preeclampsia is systematically evaluated, and the situation that the rhynchophylline can remarkably improve gestational hypertension, reduce the urine protein level and repair placenta structure and functional damage is found, so that effective intervention on the preeclampsia is realized. The invention fills the technical blank in the field, has a good application prospect, and provides a safe and controllable natural active ingredient and an application scheme thereof for preeclampsia.
Owner:ZHEJIANG UNIV

Use of water extract of amomi fructus and / or vanillic acid in preparation of drug for preventing and / or treating preeclampsia

PCT designated stageWO2026021445A1Organic active ingredientsPowder deliveryTherapeutic effectPLACENTAL FUNCTIONS
Disclosed in the present invention is the use of a water extract of Amomi fructus and / or a vanillic acid in the preparation of a drug for preventing and / or treating preeclampsia. Further disclosed in the present invention is the use of the water extract of Amomi fructus and / or the vanillic acid in the preparation of a drug for preventing and / or treating hypertension caused by preeclampsia, or a drug for preventing and / or treating proteinuria caused by preeclampsia, or a drug for reversing a reduction in placental weight caused by preeclampsia, or a drug for restoring fetal intrauterine growth restrictions caused by preeclampsia, or a drug for restoring pathological damage to placental tissue or placental dysfunction caused by preeclampsia, or a drug for reversing the reduction in placental efficiency caused by preeclampsia, or a drug for repairing colonic barrier damage or increased intestinal permeability caused by preeclampsia, or a drug for enriching the intestinal tract of a patient with preeclampsia with Bifidobacterium bifidum. The present invention overcomes the limitations of current drugs for treating preeclampsia which exhibit limited single therapeutic effects and gastrointestinal adverse reactions.
Owner:SOUTHERN MEDICAL UNIVERSITY

Application of immune costimulatory factor TNFSF9 / TNFRSF9 as marker in preparation of preeclampsia intervention product

The invention discloses an application of an immune costimulatory factor TNFSF9 / TNFRSF9 as a marker in preparation of a preeclampsia intervention product, and the immune costimulatory factor as an intervention target comprises TNFSF9 and / or TNFRSF9. According to the application, activation and immune response of immune cells of the placenta are accurately regulated and controlled by targeting a TNFSF9 / TNFRSF9 signal channel (signal axis), so that immune system disorder is effectively improved, local and systemic inflammatory response is relieved, the immune homeostasis of the placenta is recovered, and the pathophysiological process of preeclampsia is relieved.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY

Preparation method and application of nanometer serine for treating preeclampsia by targeting placental oxidative stress

The application discloses a serine nano-drug for treating preeclampsia by targeting placental oxidative stress, which can pass through the placental barrier by changing the particle size, thereby increasing the local concentration of serine in the placenta to achieve the purpose of relieving placental oxidative stress and treating preeclampsia. The placental barrier is the barrier between the placental villus tissue and the uterine blood sinus, and is an important basis for maintaining normal pregnancy. However, the placental barrier also hinders the entry of drugs into the placenta, affecting the treatment effect of drugs on placental diseases, such as preeclampsia, fetal intrauterine growth restriction and the like. The nano-drug is prepared by using nano-preparation technology to make raw drugs into particles with a nano scale, and has the advantage of penetrating through the body barrier. The amino acid involved in oxidative stress regulation, serine, is synthesized into nano-serine by using nano technology, so that serine can pass through the placental barrier by changing the particle size of nano-serine, thereby increasing the local concentration of serine in the placenta, and achieving the purpose of treating preeclampsia by reducing placental oxidative stress.
Owner:SHENZHEN MATERNITY & CHILD HEALTHCARE HOSPITAL

Evaluation model and method for predicting neonatal adverse outcome based on prenatal examination

The invention relates to an evaluation model and method for predicting a neonatal bad outcome based on antenatal examination. The main outcome of the neonatal adverse outcome comprises two parts of disease diagnosis and invasive treatment, and the neonatal adverse outcome is related to death and long-term health risk of children. The evaluation model comprises evaluation variables of weight gain during pregnancy, preeclampsia, umbilical artery S / D, congenital malformation and SGA, wherein the preeclampsia, the congenital malformation and the SGA are independent risk factors of neonatal adverse outcome. According to the scoring method, scoring is carried out based on the evaluation model, when at least one item of preeclampsia, congenital malformation, SGA and maternal congenital heart disease is' YES ', a neonatal adverse outcome high-risk group is prompted, and the higher the score is, the higher the probability of occurrence of the neonatal adverse outcome is. According to the invention, medical professionals can be rapidly helped to more effectively predict the neonatal adverse outcome, so that clinical decision-making is promoted.
Owner:XIN HUA HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

A method for dynamically predicting pre-eclampsia preterm birth risk based on pregnancy monitoring indicators

PendingCN122158147AHealth-index calculationElectronic clinical trialsProportional hazards modelPreterm Births
The present application relates to the field of medical data analysis, and more particularly to a method for dynamically predicting the risk of pre-eclampsia premature birth based on monitoring indicators during pregnancy, which comprises: obtaining an individual measured time series set and a basic time weighted average feature; obtaining a recent transient decompensation momentum factor by performing recent deterioration dynamics analysis on monitoring data near the current evaluation time; obtaining a steady-state fracture and barrier breakdown factor by jointly evaluating the evolution trend and fluctuation potential of the historical monitoring sequence; obtaining a reconstructed fusion feature vector by fusing and reconstructing the basic time weighted average feature and the steady-state fracture and barrier breakdown factor; and obtaining a dynamic prediction result of the risk of premature birth by inputting the reconstructed fusion feature vector into a Cox proportional hazards model for risk prediction, thereby solving the problem that the existing prediction method based on time weighted average and linear feature fusion cannot effectively identify recent decompensation deterioration signals and maternal-fetal state deviation risks.
Owner:JILIN UNIVERSITY